UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported): March 1, 2021

 

BioLargo, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

000-19709

 

65-0159115

(State or other jurisdiction

of incorporation)

 

(Commission File Number)

 

(IRS Employer

Identification No.)

 

 

 

14921 Chestnut St., Westminster, California

 

92683

 
 

(Address of principal executive offices)

 

(Zip Code)

 

 

Registrant’s telephone number, including area code: (888) 400-2863

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock

BLGO

OTCQB

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 8.01          Other Events

 

On March 1, 2021, BioLargo, Inc. (“we”, or the “Company”) paid in cash the outstanding principal of $600,000, and $7,371 in accrued interest, on the promissory note issued August 9, 2019, and scheduled to mature on August 9, 2021 (see Exhibit 4.01).

 

On March 1, 2021, we paid in cash the outstanding principal of $50,000, and $1,455 in accrued interest, on the remaining amount due on a line of credit in which was due on demand at any time after September 1, 2019 (see Exhibit 4.02). There is no remaining balance on this line of credit, and we no longer have the ability to draw on the line of credit.

 

Item 9.01 Financial Statements and Exhibits

 

 

Exhibit

Number

 

Exhibit Description

Form

File Date

 

4.01

 

$600,000 promissory note dated August 9, 2019

Form 10-Q

8/14/2019

 

4.01

 

Line of credit, matures September 1, 2019

Form 10-Q

5/14/2018

 

Management contract or compensatory plan, contract or arrangement

*

Filed herewith

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: March 5, 2021 

BIOLARGO, INC.

 

 

 

 

 

 

By:

 /s/ Dennis P. Calvert

 

 

 

 Dennis P. Calvert

 

 

 

 President and Chief Executive Officer

 

 

 

 
BioLargo (QB) (USOTC:BLGO)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more BioLargo (QB) Charts.
BioLargo (QB) (USOTC:BLGO)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more BioLargo (QB) Charts.